Katherine Hill
Optometrist · Portland, MENPI 1255767620
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 52.4% of the total. Reporting peaked in 2022 at $2,664 and has fallen 50.6% since, to $1,317 in 2025. Among optometrist clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $138.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$3K
- Biotissue Holdings Inc.$1K
- Oyster Point Pharma, Inc.$587
- AbbVie$519
- Dompe US, Inc.$247
- Bausch & Lomb, A Division Of Bausch Health US, LLC$158
- plus $578 from 8 others
What the payments were for
- Speaking & faculty fees$3,30049%
- Travel & lodging$75811%
- Food & beverage$2,59339%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 7 | $3,494 |
| Biotissue Holdings Inc. | 6 | $1,090 |
| Oyster Point Pharma, Inc. | 8 | $587 |
| AbbVie(2 entities) | 9 | $519 |
| Dompe US, Inc. | 2 | $247 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $158 |
| Tarsus Pharmaceuticals, Inc. | 1 | $150 |
| Sight Sciences, Inc. | 1 | $125 |
| Harrow Eye, LLC | 1 | $99 |
| Novartis | 5 | $74 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 1 | $35 |
| Convatec Inc. | 1 | $33 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$3,403
- TYRVAYA$342
- Oxervate$247
- LUMIGAN$130
- TearCare SmartLid$125
- TEARCARE(TM) (2.2) SYSTEM KIT$125
- VUITY$123
- VYZULTA$122
- RESTASIS$119
How this compares
$6,671 in reported general payments places this provider in the 95th percentile of 224 optometrist providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 233 | $345,044 |
| XiidraLifitegrast | 78 | $131,935 |
| XdemvyLotilaner | 49 | $94,303 |
| TyrvayaVarenicline Tartrate | 55 | $73,277 |
| CequaCyclosporine | 58 | $69,510 |
| Cyclosporine | 45 | $22,145 |
| Doxycycline Hyclate | 28 | $1,766 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 131 | $997 |
| ErythromycinErythromycin Base | 25 | $262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $519 | $345,044233 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $150 | $94,30349 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $587 | $73,27755 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $3,494 | $69,51058 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 optometrist providers in Maine.
Other optometrist in Portland
- Steven GoldsteinPortland$4K
- Maja KrsmanovicPortland$2K
- Amy CyrPortland$1K
- Hannah CalvelliPortland$1K
- Matthew TheesPortland$1K
- Holly McCarthyPortland$939
- Danielle PelletierPortland$885
- Timothy KearinsPortland$871
- Tracy GilesPortland$849
- Michael AnastasioPortland$810
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.